What is the Biocryst Pharmaceuticals Orladeyo Patent Situation?
Biocryst Pharmaceuticals is involved in patent litigation concerning its hereditary angioedema (HAE) drug, Orladeyo (berotralstat). The company has faced challenges to its patents, with at least one patent having been invalidated by the U.S. Patent and Trademark Office (USPTO) in an inter partes review (IPR) proceeding [1]. These proceedings are initiated by third parties seeking to challenge the validity of granted patents.
Why are companies challenging Orladeyo's patents?
Companies challenge drug patents primarily to pave the way for generic or biosimilar competition. If a patent is invalidated or found to be infringed, it can shorten the period of market exclusivity for the branded drug, allowing competitors to launch their versions sooner. In the case of Orladeyo, challenges are aimed at potentially reducing the duration of Biocryst's market exclusivity.
When does Orladeyo's patent exclusivity expire?
The patent landscape for pharmaceuticals is complex, with multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing. While specific expiration dates for all Orladeyo-related patents are not publicly detailed in the provided information, the invalidation of one patent through an IPR suggests that at least some exclusivity may be curtailed. DrugPatentWatch.com tracks and analyzes such patent information, providing details on patent status and expiration timelines [2].
What are the implications of patent challenges for Orladeyo?
The invalidation of patents can have significant financial implications for pharmaceutical companies. It can lead to a loss of market share and revenue if generic or biosimilar versions enter the market earlier than anticipated. For patients, patent challenges can potentially lead to lower drug prices and increased access to treatment options once generic versions become available.
What is Orladeyo used for?
Orladeyo (berotralstat) is a medication used for the prophylactic (preventive) treatment of hereditary angioedema (HAE) attacks in adult and pediatric patients 12 years and older [3]. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling [3].